Russia has announced a medical breakthrough with the approval of its first mRNA-based cancer vaccine, Enteromix, which will be made available free of charge to patients beginning in late 2025.
The announcement, made jointly by the Russian Ministry of Health and the Federal Medical and Biological Agency (FMBA), marks a milestone in personalized oncology treatment. The vaccine was developed by the Gamaleya National Research Center for Epidemiology and Microbiology—best known for creating the Sputnik V COVID-19 vaccine—in collaboration with leading research institutions.
Pre-clinical studies showed promising results, particularly in slowing tumor progression and preventing metastases in patients with colorectal cancer and melanoma.
According to FMBA head Veronika Skvortsova, Enteromix is designed to target each patient’s unique cancer profile using tumor-specific neoantigens. The process leverages advanced mRNA technology and artificial intelligence, enabling the creation of a personalized vaccine in less than an hour.
“This is not a universal vaccine but an individualized treatment,” explained Alexander Gintsburg, Director of the Gamaleya Center. “It activates the immune system to recognize and destroy malignant cells, offering new hope for patients battling aggressive cancers.”
Health Minister Mikhail Murashko stressed that the Russian government has fully financed the vaccine’s development to remove financial barriers for patients. With each dose valued at about 300,000 rubles (approximately $2,900), state subsidies will ensure free access for all eligible citizens.
“This is a humanitarian project that guarantees advanced care without cost to patients,” Murashko said.
Initial clinical trials will focus on patients with melanoma and small cell lung cancer, with plans to extend to other cancer types after safety and efficacy are further validated.
While the breakthrough has sparked optimism, international experts have cautioned that more data is needed to confirm long-term outcomes and scalability.
Russian President Vladimir Putin hailed Enteromix as a “new generation” of cancer treatment, saying it could become a cornerstone of global oncology if clinical results match expectations.
With rollout expected in late 2025, Russia is positioning itself as a pioneer in state-sponsored cancer immunotherapy, though the world will be closely watching how this experimental therapy performs beyond the laboratory.
